Eledon Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $196.7M
- Price
- $2.42
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.22%
- Volume
- 583.6K
About
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
Quick stats
Shares outstanding81.3M
Computed float77.2M
Float / shares95.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001404281
Websitehttps://eledon.com
AI Summary
AI-generated1/15
minorneutralother
Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
Eledon Pharmaceuticals will deliver an oral presentation at the American Society of Nephrology Kidney Week 2026 meeting in Denver, October 21-25.
The presentation will cover patient-reported outcomes from the Phase 2 BESTOW trial comparing tegoprubart to tacrolimus for prevention of rejection in kidney transplant recipients.
Dr. Andrew B. Adams of the University of Minnesota will present on October 23, 2026; the announcement contains no new clinical data.